The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Open accessAbstract
SUMMARY Background: We compared the safety and efficacy of three antiretroviral regimens started in pregnancy: dolutegravir (DTG)+emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF); DTG+FTC/tenofovir disoproxil fumarate (TDF); and efavirenz (EFV)/FTC/TDF. Methods: Women with HIV-1 infection at 22 sites in 9 countries were randomized 1:1:1 at 14–28 weeks’ gestation to start each regimen (open-label). The primary efficacy outcome was virologic non-inferiority at delivery (−10% margin) of the combined DTG groups versus the EFV group, with superiority tested in a pre-planned secondary analysis. Primary safety outcomes, compared pairwise among treatment groups, were occurrence of any adverse pregnancy outcome (preterm delivery, small for gestational age, stillbirth, or spontaneous abortion) and occurrence of maternal and infant adverse events, grade ≥3. Primary analyses were intention-to-treat (ITT). Findings: We enrolled 643 women: 217 DTG+FTC/TAF, 215 DTG+FTC/TDF, 211 EFV/FTC/TDF. Enrollment medians were 22 weeks’ gestation, HIV-1 RNA 903 copies/mL (28% <200 copies/mL), and CD4 count 466 cells/uL. Delivery HIV-1 RNA was available for 605 (94%) women: 395 (98%) in the combined DTG groups had delivery HIV-1 RNA <200 copies/mL vs. 182 (91%) in the EFV group (difference 7% [95%CI 2%, 11%]; p=0·005). Fewer women assigned to DTG+FTC/TAF (24%) experienced the composite adverse pregnancy outcome than women assigned to either DTG+FTC/TDF (33%, difference −9% [95% CI −17%, −0·3%]; p=0·043) or EFV/FTC/TDF (33%, difference −9% [95%CI −17%, −0·1%]; p=0·047). Grade ≥3 maternal and infant adverse events did not differ by group. Preterm delivery was significantly lower with DTG+FTC/TAF (6%) than EFV/FTC/TDF (12%, difference −6% [95%CI −12%, −0·9%]; p-value = 0·023). Stillbirth was more frequent with DTG (non-significant, p=0.064). Neonatal mortality was more frequent with EFV/FTC/TDF (5%) than DTG+FTC/TAF (1·0%, p=0·019) or DTG+FTC/TDF (1·5%, p=0·050). Interpretation: When started in pregnancy, DTG-containing regimens had superior virologic efficacy at delivery compared with EFV/FTC/TDF. DTG+FTC/TAF had the lowest frequency of the composite adverse pregnancy outcome and of neonatal death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, L., Oza, S., Hogan, D., Chu, Y., Perin, J., Zhu, J., Lawn, J. E., Cousens, S., Mathers, C., & Black, R. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31593-8 · Cited by 3,453
Dolutegravir plus two different prodrugs of tenofovir to treat HIV
Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902824 · Cited by 723
Self-citationCommittee Opinion No. 700: Methods for estimating the due date
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002046 · Cited by 683
Ultrasound‐based gestational‐age estimation in late pregnancy
Papageorghiou, A. T., Kemp, B., Stones, W., Ohuma, E. O., Kennedy, S. H., Purwar, M., Salomon, L. J., Altman, D. G., Noble, J. A., Bertino, E., et al. (2016) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.15894 · Cited by 179
Cited by
Gandhi, R. T., Bedimo, R., Hoy, J. F., Landovitz, R. J., Smith, D. M., Eaton, E. F., Lehmann, C., Springer, S. A., Sax, P. E., Thompson, M. A., et al. (2023) · JAMA · doi:10.1001/jama.2022.22246 · Cited by 557
Self-citationGandhi, R. T., Landovitz, R. J., Sax, P. E., Smith, D. M., Springer, S. A., Günthard, H. F., Thompson, M. A., Bedimo, R. J., Benson, C. A., Buchbinder, S. P., et al. (2025) · JAMA · doi:10.1001/jama.2024.24543 · Cited by 265
Self-citation
Metadata
- Authors
- Lockman, S., Brummel, S. S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A., Jean-Philippe, P., Johnston, B., Krotje, C., Fairlie, L., Hoffman, R. M., Sax, P. E., Moyo, S., Chakhtoura, N., Stringer, J. S., Masheto, G., Korutaro, V., Cassim, H., Mmbaga, B. T., João, E., Hanley, S., Purdue, L., Holmes, L. B., Momper, J. D., Shapiro, R. L., Thoofer, N. K., Rooney, J. F., Frenkel, L. M., Amico, K. R., Chinula, L., Currier, J., Best, B. M., Blanchette, C., Browning, R., Cheng, Y., Fox, A., Jaliaah, N., Knowles, K., Mirochnick, M., Murtaugh, W. A., Patras, E., Pinilla, M., van Wyk, J., & Whalen, F.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 397
- Issue
- 10281
- Pages
- 1276-1292
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3142355365
- Cited by
- 164
- References
- 4
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00314-7
- The paper
- Lockman, S., Brummel, S. S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A., Jean-Philippe, P., Johnston, B., Krotje, C., Fairlie, L., Hoffman, R. M., Sax, P. E., Moyo, S., Chakhtoura, N., Stringer, J. S., Masheto, G., Korutaro, V., Cassim, H., Mmbaga, B. T., . . . Whalen, F. (2021). Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)00314-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.